EQS-News: Geovax promises continuous support for innovation of vaccines, transparency and public health 18.02.25

Geovax vaccine development programs align with anticipated HHs focus on vaccine safety, diversification and internal biosecurity

Atlanta, GA – February 18, 2025 (Newmediawire) – Geovax Labs, Inc. (Nasdaq: Govx), leader in the development of vaccines and immunotherapy, congratulated Robert F. Kennedy, Jr. for his confirmation of secretary of the US Health and Services (HHS). The appointment of RFK Jr. offers a significant opportunity for medical innovation, transparency and public confidence, strengthening national priorities, such as vaccine safety, diversified vaccine platforms and consolidating domestic production. Geovax is ready to support these initiatives by providing next generation vaccines and advanced technology of manufacturing vaccines that improve biosecurity, public health and vaccine confidence.

Geovax’s commitment to a sturdy, transparent and safe future vaccine

Geovax’s mission is closely aligned with the priorities of the policy of the new administration, especially in reducing the dependence on foreign pharmaceutical supply chains, increasing the safety and durability of the vaccine and ensuring access to underestimated populations. The Vaccinia Ankara (MVA) platform of the company offers a promising alternative to other vaccine technologies, such as MRI, offering broad, sustainable spectrum immunity, on several infectious diseases, through a secure vaccine platform.

The key initiatives that support the objectives for the safety and transparency of the vaccine include:

• Diversified Development of Vaccine -Geovax’s Geo-CM04S1, a Covid-19 next generation vaccine and geo-MVA, a Mpox and Variole vaccine, for double, align Advocacy for alternative vaccine platforms beyond the mRNA. These vaccines are designed to provide long -term immunity with a well -documented safety profile.
• Transparency as a pillar of public trust – As David Dodd, president and CEO of Geovax, stressed, restoring confidence in vaccines requires clear communication, open regulatory processes and full transparency in terms of safety, effectiveness and potential risks. Geovax supports the call for greater responsibility of the industry and public involvement, ensuring that the development of the vaccine is aligned with the highest standards of ethical science.
• Strengthening US biosecurity – The anticipated capacities of manufacturing the internal vaccines of Geovax strengthen the bipartidist legislative commitment to reduce the dependence on the foreign pharmaceutical supply chains, thus increasing the national preparation of the pandemic.
• Ethical development of vaccines and public confidence – Geovax includes open regulatory processes, rigorous standards of safety and public access to data, ensuring confidence in its vaccines. These principles are aligned with the call for increased examination and transparency in the development and approval of vaccines.
• Fair access and global preparation -With cost-effective technology, which does not require ultra-cold storage, Geovax vaccines are suitable for internal and global distribution, ensuring broad access to critical immunizations, especially for immunocompromised and underestimated communities.

David Dodd: “Transparency is the key to restoring vaccine trust”

Reflecting on the challenges of hesitation of the vaccine, David Dodd was a vocal lawyer for transparency in the development of vaccines and regulatory processes. In a recent option, he stressed: “Trust in vaccines has become a critical fighting ground for public health. Open and sincerely approaching public concerns is the only way to develop the difference bigger between science and skepticism. Transparency is a necessity, not a Option. (https://www.genengnews.com/topics/translational-medicine/a-call-to-acction-Building-vaccine-frust-though-transparency/)

This perspective directly supports the stated objectives to strengthen the public trust, reduce the opacity regulations and ensure the safety of the vaccine through independent supervision. Geovax’s proactive approach for the transparent development of the vaccine is a model for the management of responsible biotechnology.

A new era for US health and pandemic preparation

The confirmation of RFK Jr. as Secretary HHS offers a renewed opportunity in support of diversifying vaccines, transparency and strategic initiatives of Biomania. The innovative pipelina of the Geovax vaccine supports these goals, positioning the company as a vital partner in protecting national and global public health.

The Strategy for the development of the Geovax vaccine is based on successful national initiatives, such as the operating speed and the Nextgen project, by prioritizing the pandemic training and biosecurity resistance. By continuous involvement with federal agencies and global health organizations, the company tries to accelerate the development of vaccines, expand domestic production and improve pandemic response efforts.

David Dodd, president and CEO of Geovax, said: “Confirmation of Secretary Kennedy presents an opportunity to redefine public health, with greater emphasis on safety, accessibility and innovation. Geovax proudly supports the commitment to reduce dependence on foreign pharmaceutical supply chains, diversify vaccine technology and restore confidence in solutions Public health. Medical to advance a safer and more resistant to medical care.

About Geovax

Geovax Labs, Inc. It is a clinical biotechnology company that develops new vaccines for many of the most threatening infectious diseases in the world for solid tumor cancers. The main clinical program of the company is Geo-CM04S1, a Covid-19 next generation vaccine for which Geovax recently received a Barda funded contract to sponsor a clinical study of 10,000 participants in phase 2B to evaluate the effectiveness of Geo-CM04S1 by an approved approved approved Covid-19 vaccine. In addition, Geo-CM04S1 is currently in phase tribunes 2 clinical studies, being evaluated as (1) a primary vaccine for immunocompromisic patients, such as those suffering from hematological cancer and other patient populations for which current COPID authorized vaccines -19 are insufficient, (2) a rappel vaccine in patients with chronic lymphocyte leukemia (CLL) and (3) a more robust, more durable Covid-19 Booster among healthy patients who have previously received MRNA vaccines. In oncology, the main clinic program evaluates a new therapy directed by solid oncolitic tumor genes, Gedeptin®, after recently completed a 1/2 multicentric phase clinical study for advanced head and neck cancers. A clinical study in phase 2 is planned in the first recurrent head and neck cancer, evaluating Gedeptin® combined with an immune control point inhibitor. Geovax has a strong IP portfolio in support of its product technologies and candidates, having worldwide rights for its technologies and products. The company has a management team that has determined the significant creation of values ​​on several life science companies in the last few decades. For more information on the current state of our clinical studies and other updates, visit our website: www.geovax.com.

Prospective statements

This version contains prospective statements about Geovax’s business plans. The words “believe”, “looking forward”, “more”, “estimation”, “continues”, “anticipates”, “intends”, “should”, “plan”, “could” target “,” potential Potential “” is probably “,” will “,” wait “and similar expressions, as they relate to us, are intended to identify prospective statements. We have based these prospective statements largely on our current expectations and projections about future events and financial tendencies that we believe can affect our financial status, operations results, business strategy and financial needs. Real results may differ significantly from those included in these statements due to a variety of factors, including if: Geovax is able to achieve acceptable results from the ongoing or future clinical studies of its investigation products, the immuno-oncology products and the vaccines Preventive can cause the desired answers, and those products or vaccines can be used effectively, viral vector technology of Geovax adequately amplifies the immune responses to cancer antigens, Geovax can develop and manufacture its immuno-encology and preventive vaccines with the desired features in a timely man. Geovax will actually prevent infections targeted in humans, immuno-oncology products of Geovax, Geovax immuno-oncology products, Geovax immuno-tocology products, Geovax immuno-oncology immuno-encology products and preventive vaccines will receive regulatory approvals necessary to be authorized and marketed, Geovax increases capital Required to complete the development, there is development of competitive products that may be more efficient or easier to use than products Geovax, Geovax will be able to conclude favorable manufacturing and distribution agreements and other factors, on which Geovax has no control.

Additional information about our risk factors is contained in our periodic reports on form 10-Q and the 10-K form we have submitted and we will submit to the sec. Any prospective statement made by us here speaks only from the date it is made. The factors or events that could make our real results differ from time to time and it is not possible to predict them all. We assume no obligation to publicly update any prospective statement, either as a result of new information, future or other evolutions, unless they can be requested by law.

Company contact:
[email protected]
678-384-7220

Relationships with Investors Contact:
[email protected]
212-698-8696

Media contact:
[email protected]
202-779-0929

View the original version on www.newmediawire.com

News source: Geovax, Inc.